News at CenExel

CenExel Acquires California Neuroscience Research

Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...

PCRS in Depression and Psychosis Trials

CenExel is proud to highlight the poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2020, Miami, FL. ABSTRACT Introduction: Depression and psychosis clinical trials share a crucial commonality of perpetually and...

Esketamine Receives Support from 2 FDA Committees

Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...

PCRS in Depression Clinical Trials

CenExel is proud to highlight the poster presented at the Annual International Society for CNS Clinical Trials and Methodology (ISCTM) Meeting, February 2019, Washington, DC. ABSTRACT Introduction: Although the placebo effect continues to persist within depressive...

Depression Treatment Gaithersburg

Depression treatment Gaithersburg. If you are experiencing depression and no medications have really helped, maybe one of our trials will.

PCRS on Subjects with Major Depression​

CenExel is proud to highlight the poster presented at the Annual CNS Summit Meeting,​ November 2018, Boca Raton, FL.​ ​ABSTRACT Introduction: This investigation is the first known that empirically explores if educating subjects about key causes of the placebo effect...